Immunotherapy in breast cancer treatment
Author:
Bhaskar Pranav1, Sahu Bijayani2
Affiliation:
1. Department of Biochemistry, Panjab University, Chandigarh - 160014, India 2. Department of Biomedical Sciences, University of North Dakota, USA.
Abstract
Breast cancer is one of the most common types of cancer affecting women worldwide. In recent years, immunotherapy has emerged as a promising treatment option for breast cancer. Immunotherapy refers to the use of treatments that enhance the body's natural immune response to fight cancer. This type of therapy has shown promising results in patients with breast cancer, offering the potential for improved outcomes and quality of life. There are several types of immunotherapies used in the treatment of breast cancer, including immune checkpoint inhibitors, cancer vaccines, adoptive cellular therapy, oncolytic virus therapy, and immunomodulators. These treatments work by targeting specific components of the immune system to enhance the immune response against cancer cells. Although immunotherapy holds promise for the treatment of breast cancer, there are a number of drawbacks. Currently, only a subset of patients with breast cancer are eligible for immunotherapy, and not all patients with breast cancer will respond to these treatments. Additionally, immunotherapy can cause immune-related side effects, and can be expensive, limiting access for some patients. In spite of these limitations, the field of immunotherapy for breast cancer is rapidly evolving, with ongoing research aimed at improving the effectiveness and safety of these treatments. The future of immunotherapy in the treatment of breast cancer is promising, with a focus on personalized immunotherapy, combination therapies, biomarker discovery, immune monitoring, and the development of new immunotherapies. Overall, immunotherapy offers a promising treatment option for patients with breast cancer. Through continued research and innovation, it is hoped that immunotherapy will become a standard treatment option, offering improved outcomes and quality of life for patients with breast cancer.
Publisher
The Applied Biology & Chemistry Journal
Subject
Community and Home Care,Marketing,Organizational Behavior and Human Resource Management,Strategy and Management,Drug Discovery,Pharmaceutical Science,Pharmacology,General Medicine,General Medicine,General Medicine,General Medicine,General Medicine,General Earth and Planetary Sciences,General Environmental Science,General Earth and Planetary Sciences,General Environmental Science,General Medicine
Reference43 articles.
1. Arnold, D., Wiltzius, J. J., Chia, S., & Krop, I. E. (2012). Thalidomide in the treatment of breast cancer. Cancer Treatment Reviews, 38(5), 455-462. https://doi.org/10.1016/j.ejps.2020.105302 2. Ascierto, M. L., Kmieciak, M., Idowu, M. O., Manjili, R., Zhao, Y., Grimes, M., Dumur, C., Wang, E., Ramakrishnan, V., Wang, X.-Y., Bear, H. D., Marincola, F. M., & Manjili, M. H. (2012). A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Research and Treatment, 131(3), 871–880. https://doi.org/10.1007/s10549-011-1470-x 3. Atallah-Yunes, S. A., & Robertson, M. J. (2022). Cytokine based immunotherapy for cancer and lymphoma: Biology, challenges and future perspectives. Frontiers in Immunology, 13, 872010 https://doi.org/10.3389/fimmu.2022.872010 4. Cardillo, F., Bonfim, M., daSilva Vasconcelos Sousa, P., Mengel, J., Ribeiro Castello-Branco, L. R., & Pinho, R. T. (2021). Bacillus Calmette–Guérin Immunotherapy for Cancer. Vaccines, 9(5), 439. https://doi.org/10.3390/vaccines9050439 5. Cheever, M. A., & Higano, C. S. (2011). PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine. Clinical Cancer Research, 17(11), 3520–3526. https://doi.org/10.1158/1078-0432.CCR-10-3126
|
|